A PILOT STUDY OF PENTOXIFYLLINE IN REDUCING SYSTEMIC INFLAMMATION AND IMPROVING

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective, single center, single arm, open-label, pilot study evaluating the potential efficacy and safety of pentoxifylline (PTX), a phosphodiesterase inhibitor that blocks tumor necrosis factor-? (TNF-?), in the treatment of endothelial dysfunction in twelve HIV-infected patients seen at the Indiana University Medical Center with CD4 cell counts greater than 350/¿L and not currently receiving antiretroviral therapy. Enrolled subjects will have their brachial flow-mediated dilation (FMD), a measure of endothelial function, and other cardiovascular and immunologic parameters measured at baseline and again after 4 and 8 weeks of treatment with PTX. Each individual subject will be followed for approximately 10 weeks. The total duration of this study will be approximately 8 months.